bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P3-07-14: Prosigna® intrinsic subtyping predicts response to neoadjuvant combination therapy in study that includes herceptin within HER2+ (IHC) patients
Authors: Santonja Á , Ribelles N , Jiménez-Rodríguez B , Sánchez Rovira P , Álvarez M , Vicioso L , Isabel Fernandez A , de Luque V , Fernández de Sousa C , Villar E , Zarcos I , Ramírez C , González-Hermoso C , Jeiranian A , Dowidar N , Schaper C , Buckingham W , Ferree S , Jiménez A , Prat A , Alba E 
Published: May 2016

Abstract
Background: The role of the HER2-enriched (HER2E) subtype determined by the Prosigna Assay in the neoadjuvant setting has remained largely uncharacterized. In this study, we examine whether Prosigna can identify a subgroup of HER2+ patients for whom combination neoadjuvant therapy that includes trastuzumab (Herceptin) is associated with a greater likelihood of pathological complete response (pCR). Methods: In this single-arm retrospective analysis, 75 patients determined to be HER2+ by IHC were treated with a neoadjuvant regimen (NAC) consisting of 8-12 cycles of anthracyclines and taxanes as well as Herceptin. The Prosigna Assay was performed on the NanoString nCounter® Dx Analysis System at HU Virgende la Victoria de Málaga/CIMES-UMA. pCR was used as the endpoint for this study and was determined using the Miller & Payne scoring criteria. Results: Mean patient age for this study population was 49 (±11.1yr) and all patients were determined to be HER2+ by IHC. The overall pCR rate in this patient population was 46.2%. Of the 75 patient samples analyzed for this study, 59 (78.6%) were HER2E, 4 (5.3%) were Luminal A and 12 (16.1%) were Luminal B, as identified by the Prosigna Assay. Of the 16 tumors classified as Luminal (A or B) by Prosigna within this HER2+ population, only 2 (12.5%) responders were observed. Categorical analysis revealed that Prosigna subtype predicted response to a NAC regimen combined with Herceptin (Odds ratio [Her2E vs. non-Her2E]=6.4, p=0.023). Further analysis of the Her2E subtype revealed that tumors with profile expression that correlated well with the prototypical Her2E centroid were significantly more likely to respond to combination NAC and Herceptin (Odds ratio [Unit increase of 1 in Her2E correlation]=88.2, p=0.004). Conclusions: The results of this study indicate that HER2+ patients with greater correlations to the HER2E subtype have an increased likelihood of response to combination neoadjuvant regimens that included HER2-targeted therapy.
Citation Format: Santonja Á, Ribelles N, Jiménez-Rodríguez B, Sánchez Rovira P, Álvarez M, Vicioso L, Isabel Fernandez A, de Luque V, Fernández de Sousa C, Villar E, Zarcos I, Ramírez C, González-Hermoso C, Jeiranian A, Dowidar N, Schaper C, Buckingham W, Ferree S, Jiménez A, Prat A, Alba E. Prosigna® intrinsic subtyping predicts response to neoadjuvant combination therapy in study that includes herceptin within HER2+ (IHC) patients. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-14.
Abstract P4-14-18: Phase I study of single-agent pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with ErbB2+ metastatic breast cancer
Authors: Xu B , Ma F , Chen S , Li Q , Yang F , Zhang Y , Chen X , Zhong D , Zhang G 
Published: May 2016

Abstract
Pyrotinib is a novel small molecule irreversible pan-ErbB receptor tyrosine kinase inhibitor. This phase I study was designed to evaluate the safety, pharmacokinetics and antitumor activity of pyrotinib in Chinese patients with ErbB2+ metastatic breast cancer (n=38). The majority of patients were previously treated with multiple lines (≤5) of anti-tumor regimens including trastuzumab. The dose-escalation study was conducted at 80, 160, 240, 320, 400 and 480 mg levels in patients receiving oral pyrotinib with food once daily on a 28-day cycle. Dose-limiting toxicity (DLT) was grade 3 diarrhea, which occurred in two out of two patients treated with 480mg pyrotinib during the dose-escalation. Therefore, the maximum tolerated dose (MTD) of pyrotinib was determined to be 400 mg per day. In general, pyrotinib was safe and well tolerated when administered to patients. The majority of adverse events which occurred in the study were grade I and II. The pharmacokinetic results showed linear characteristics along the range of doses tested, and supports a once daily dosing regimen. The overall objective response rate (ORR) was 52.8% and disease control rate (DCR) was 80.6% in 36 patients (19 PR and 10 SD), with the highest ORR of 55.6% (5/9) and 87.5% (7/8) observed in 320 mg and 400 mg cohorts, respectively. The median duration of response was 32.3 weeks. In addition, 3 (8.3%) subjects achieved stable disease for at least 24 weeks. Kaplan-Meier median progression-free survival (PFS) was 35.3 weeks (95%CI: 23.6∼39.9 weeks) among all subjects treated with 80-400 mg, and the median PFS for 320 mg and 400 mg cohorts was 39.9 weeks (95%CI: 31.1∼47.4 weeks). Based on tolerability, safety, PK and efficacy data of 6 dose-cohorts, 320 mg and 400mg of pyrotinib once daily could be considered a recommended regimen for Phase II studies. The promising antitumor activity of pyrotinib observed in patients with ErbB2+ metastatic breast cancer, who had previous treatment with anthracyclines, taxanes, and trastuzumab, warrants its further study (ClinicalTrials.gov number, NCT01937689).
Citation Format: Xu B, Ma F, Chen S, Li Q, Yang F, Zhang Y, Chen X, Zhong D, Zhang G. Phase I study of single-agent pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with ErbB2+ metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-14-18.
Abstract A23: Fe en Acción/Faith in Action: Promotion of cancer screening among churchgoing Latinas
Authors: Elder John P. , Arredondo Elva M. , Haughton Jessica , Perez Lilian G. , Martínez María Elena 
Published: May 2016

Abstract
Objectives: To present outcomes of a controlled two-group clustered randomized community trial promoting breast, cervical, skin and colorectal cancer screening (CS) among churchgoing Latinas through promotoras (lay health advisors).
Design: Sixteen churches were randomly assigned either to the CS or a physical activity (PA) condition. Sixteen promotoras at the 8 CS churches intervened at the individual- (knowledge and beliefs), interpersonal- (social support and sharing personal experiences), organizational- (space at church for program activities), and environmental- (access to health care) levels to affect changes in target behaviors. Approximately 27 women per church were recruited to participate in the study.
Measurements: The study's primary outcome was being current on recommended mammography, clinical breast exams, sigmoidoscopy and colonoscopy, fecal occult blood test, and cervical cancer tests based on self-report at baseline and 12 and 24 months following implementation of intervention activities. Participants were 436 Latinas (aged 18-65 years; 91% Mexican immigrants) who met activity-level criteria for the PA condition, attended church at least four times per month, and lived near their church. Enrolled participants were asked to complete measures assessing PA and cancer screening as well as their correlates at each measurement point (e.g., health insurance, perceived barriers to screening, and knowledge about each cancer).
Results: The CS intervention had a significant positive impact on self-reported uptake of mammography and breast exams. Pap smear tests were already reported at high baseline rates and did not change as a function of the intervention. Colorectal cancer screening rates were low and did not improve with the intervention.
Summary: Promotoras working in their own churches can have a significant impact on promoting breast cancer screening among Latinas. The use of colon cancer screening remains a difficult challenge, however, with improved methods still being needed.
Citation Format: John P. Elder, Elva M. Arredondo, Jessica Haughton, Lilian G. Perez, María Elena Martínez. Fe en Acción/Faith in Action: Promotion of cancer screening among churchgoing Latinas. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr A23.
Abstract A44: Using CBPR to extend prostate cancer education, counseling, and screening opportunities to urban-dwelling African Americans
Authors: Ross Levi , Johnson Jarrett , Smallwood Stacy W. , Luque John (Juan) , Tedders Stuart H. , Airhihenbuwa Collins O. ,   MAN UP Prostate Cancer Advocates
Published: May 2016

Abstract
Community-based participatory research (CBPR) is becoming one of the dominant approaches for bringing evidence- and consensus-based cancer prevention and control practices to medically underserved communities. There are many examples of how CBPR has been useful for generating culturally specific solutions for different health issues that affect African-Americans. However, few examples exist in the literature on how the CBPR approach can be applied to address prostate cancer. This presentation will describe a collaborative process for linking inner-city, African-American men to free prostate cancer education, physician counseling, and screening opportunities (prostate-specific antigen (PSA) testing and digital rectal examination (DRE)). The site of this community-based participatory project was the city of Buffalo, located in Erie County, New York. A total of 55 men from 16 zip codes attended the three hour community event. All 55 attendees received free prostate cancer education, and 35 (63%) chose to undergo screening. Of the 35 men who were screened, the majority (29/35= 83 %) were African-American. Event planners were pleased that nearly three fourths of those screened (26/35=74 %) were first-time screeners. All event attendees (55/55=100%), even those who elected not to screen, had an informed screening discussion with one of the attending urologists. All participants were mailed their screening results within 2 weeks, along with personalized instructions for following up with their primary care physician.The collaborative, community-academic process that will be described includes the following: (1) planning and conducting a community needs assessment to contextualize local prostate cancer issues, (2) organizing town and gown event planning, and (3) manipulating aspects of the built environment to build an infrastructure within the community to address disparities in screening opportunities. This presentation will conclude with a description of lessons learned that can help others develop and implement similar activities in other communities.
Citation Format: Levi Ross, Jarrett Johnson, Stacy W. Smallwood, John (Juan) Luque, Stuart H. Tedders, Collins O. Airhihenbuwa, MAN UP Prostate Cancer Advocates. Using CBPR to extend prostate cancer education, counseling, and screening opportunities to urban-dwelling African Americans. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr A44.
Abstract B90: Predictors of HPV vaccine initiation and completion among Hispanic mothers of 11-17 year old daughters living along the Texas-Mexico border
Authors: Morales-Campos Daisy Y. , Parra-Medina Deborah A. 
Published: May 2016

Abstract
Background: Cervical cancer incidence and mortality are higher for Hispanic women along the Texas-Mexico border than for other female population groups. Incidence could be reduced if teenaged Hispanic girls received the HPV vaccine before they became sexually active. However, few Hispanic girls compared to U.S. girls receive all three HPV vaccine doses (31% vs 36%), which prevent cervical cancer. Mothers are crucial to the success of HPV vaccine uptake efforts, but few studies have examined predictors of vaccine initiation and completion. The purpose of this study is to assess predictors (socio-demographics, HPV and vaccine knowledge, and vaccine self-efficacy) of vaccine initiation and completion.
Methods: We utilized baseline data from an outreach and education program utilizing promotoras and peer educators to deliver health education to mothers and daughters to increase HPV knowledge and promote HPV immunization. Our analyses utilized data from mothers of never vaccinated girls (n=371) to examine the association between the predictors and vaccine initiation and completion. To control for potential confounders, we conducted multivariable logistic regression analyses.
Results: Findings showed both health insurance (Initiators AOR: 0.27; 95% CI= .09, .79; Completers AOR: 0.29; 95% CI= .10, .83) and program status (Initiators AOR: 3.04; 95% CI= 1.76, 5.26; Completers AOR: 2.21; 95% CI= 1.27, 3.58) were associated with HPV vaccine initiation and completion among mothers. Results also showed preferred language (AOR: 0.15; 95% CI= .04, .53) and health status (AOR: 0.52; 95% CI= .29, .92) were associated with series initiation.
Conclusions: Findings suggest mothers who spoke English, had health insurance, and reported having good health were at lower odds of vaccine initiation. Also, mothers with health insurance also had lower odds of series completion. Mothers who participated in the program compared to the brochure only group were more likely to initiate and complete the vaccine series. These findings assist in identifying appropriate intervention strategies to enhance vaccine initiation in border communities at risk for cervical cancer.
Citation Format: Daisy Y. Morales-Campos, Deborah A. Parra-Medina. Predictors of HPV vaccine initiation and completion among Hispanic mothers of 11-17 year old daughters living along the Texas-Mexico border. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr B90.
Abstract C28: Racial and ethnic disparities in mammography utilization among women with intellectual disabilities: An exploratory mixed methods approach
Authors: Arana Evelyn 
Published: May 2016

Abstract
Background: Racial and ethnic disparities in mammography utilization among the general population persist to this day. Women with intellectual disabilities have much lower rates of mammography receipt compared to women without ID and are diagnosed with breast cancer at more advanced stages. Among women with ID, the diverse perceptions and experiences among different racial and ethnic groups surrounding mammography utilization are unknown. The purpose of this study is to conduct a mixed methods study to explore racial and ethnic differences in mammography utilization and experience among women with ID who are Black/African American, Hispanic, and non-Hispanic White.
Specific Aims:
1. Collect mammography medical records and demographic information from Black/African American, Hispanic, and non-Hispanic White women with ID to determine general trends in mammography utilization from 2010-2013.
2. Determine the barriers and facilitators contributing to mammography utilization among different racial and ethnic groups of this population via in-depth interviews.
3. Explore how culture may affect the social interactions that in turn may affect mammography utilization among this population.
This approach is innovative as it combines quantitative and qualitative methodologies to data collection among a priority population. The proposed research is significant because it will increase awareness on the different racial and ethnic perspectives regarding mammography utilization among women with ID. In the long-term, the results from this research may improve the delivery of appropriate healthcare to this population to achieve a reduction in mammography disparities. In addition, expected results from this research can be considered when planning breast cancer prevention interventions within this population and may be used to enhance the quality of healthcare for women with ID. This research is funded by AHRQ GRANT11714050. Preliminary findings are expected for November 2015.
Citation Format: Evelyn Arana. Racial and ethnic disparities in mammography utilization among women with intellectual disabilities: An exploratory mixed methods approach. [abstract]. In: Proceedings of the Eighth AACR Conference on The Science of Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Nov 13-16, 2015; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2016;25(3 Suppl):Abstract nr C28.
Abstract A10: Oncogenomic analysis of IGF-IR driven mammary tumors identifies a potential cell of origin and mechanisms of tumor recurrence
Authors: Jones Robert A. , Campbell Craig I. , Watson Katrina L. , Moorehead Roger A. 
Published: May 2016

Abstract
Genetically engineered mice are valuable tools for understanding the genetic events that contribute to breast cancer development and progression. We have previously generated a doxycycline (Dox) inducible model of breast cancer, MTB-IGFIR, in which overexpression of the human type-I IGF receptor (IGF-IR) leads to the rapid induction of ER-mammary tumors with mixed luminal and basal features. Following Dox withdrawal and subsequent transgene downregulation, a subset of tumors escape IGF-IR dependence and spontaneously recur with evidence of an epithelial-mesenchymal transition (EMT). To gain insight into the molecular pathways that drive primary and recurrent tumor growth in MTB-IGFIR mice, we carried out gene expression profiling and DNA copy number analysis. Gene-set enrichment analysis (GSEA) revealed expression of an Akt oncogenic signature in primary tumors, consistent with downstream signaling mediated by IGF-IR. Interestingly, primary tumors also expressed a luminal progenitor gene signature suggesting a potential cell of origin. Accordingly, flow cytometric analysis of Dox-pulsed mice showed that high expression of the IGF-IR transgene was confined to EpCAM+/high Sca-1− cells, a putative ER- alveolar progenitor population. Recurrent tumors were found to express a mammary stem cell (MaSC) gene signature, which is consistent with their more mesenchymal phenotype as well as increased cell cycle pathway activity. While aCGH analysis identified few genomic changes in primary tumors, recurrent tumors exhibited gains and losses in known oncogenes and tumor suppressors including MET receptor, YAP1 and p16Ink4a/p19ARF. Integration of mRNA and copy number data confirmed altered expression of these genes at the transcriptional level. Taken together, these results suggest IGF-IR drives tumor initiation in an ER- luminal progenitor cell population in part through activation of the Akt pathway and that multiple genetic alterations contribute to the acquisition of oncogene independence and tumor relapse.
Citation Format: Robert A. Jones, Craig I. Campbell, Katrina L. Watson, Roger A. Moorehead. Oncogenomic analysis of IGF-IR driven mammary tumors identifies a potential cell of origin and mechanisms of tumor recurrence. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Breast Cancer Research; Oct 17-20, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(2_Suppl):Abstract nr A10.
Abstract A51: Investigation of the DEK oncogene as a blood biomarker for breast cancer
Authors: Sendilnathan Arun , Charif Mahmoud , Shaughnessy Elizabeth , Lewis Jaime D. , Radhakrishnan Neetu , Lower Elyse , Lanigan Catherine , Kumar Harriet , Wise-Draper Trisha M. , Vinnedge Lisa Privette 
Published: May 2016

Abstract
Breast cancer (BC) is one of the leading causes of death for women in the United States. This is due, in part, because women wait too long to get a diagnosis or the disease returns, sometimes years later, due to ineffective treatment. Therefore, it is critically important to identify biomarkers that can better inform clinicians while providing a screening test more amenable to patients than mammograms. We are investigating the feasibility of using DEK protein levels in patient plasma as a biomarker for disease stage and prognosis. DEK is a chromatin-organizing protein that functions in DNA replication and repair, transcription, and mRNA splicing. The DEK oncoprotein is highly upregulated in many types of cancer including breast, head and neck, and melanoma. Using human cell culture and murine models, our previous studies have shown that DEK is functionally important for the promotion of cellular growth, invasion/metastasis, drug resistance, and breast cancer stem cell maintenance. Work by the Markovitz laboratory indicated that DEK is secreted by macrophages as a pro-inflammatory signaling molecule and can be internalized by neighboring cancer cells to promote typical DEK functions. This led to our hypothesis that DEK may be present in the plasma of cancer patients. In fact, the detection of DEK protein in urine is currently being explored as a diagnostic biomarker for bladder cancer. To test this hypothesis, we collected peripheral blood from patients with newly diagnosed, untreated BC (irrespective of the clinical stage) and age- and ethnicity-matched normal healthy controls. Plasma was separated from the samples and subjected to DEK specific ELISA (Cusabio, Wuhan, China). Preliminary results demonstrate that DEK is indeed present in the plasma of BC patients and we are currently comparing these levels to normal healthy controls. Further analyses are ongoing to determine whether DEK levels correlate with pertinent clinical and pathological variables including age, tumor stage, and ER/PR/HER-2 status. In addition, we are examining if DEK levels can predict response to various treatment modalities and risk of relapse. These data will be important to verify DEK plasma measurements as a clinically useful test and may give insight to future personalized and targeted treatment strategies for BC.
Citation Format: Arun Sendilnathan, Mahmoud Charif, Elizabeth Shaughnessy, Jaime D. Lewis, Neetu Radhakrishnan, Elyse Lower, Catherine Lanigan, Harriet Kumar, Trisha M. Wise-Draper, Lisa Privette Vinnedge. Investigation of the DEK oncogene as a blood biomarker for breast cancer. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Breast Cancer Research; Oct 17-20, 2015; Bellevue, WA. Philadelphia (PA): AACR; Mol Cancer Res 2016;14(2_Suppl):Abstract nr A51.